DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/dsdfsr/epicast_report) has announced the addition of the "EpiCast Report: Graft-Versus-Host Disease - Epidemiology Forecast to 2023" report to their offering.
Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host's cells as foreign. GVHD can progress from mild to severe forms as either acute GVHD (aGVHD) or chronic GVHD (cGVHD). Both aGVHD and cGVHD commonly affect organs such as the skin, gastrointestinal (GI) tract, liver, oral mucosa, and eyes.
To forecast the diagnosed incident cases of aGVHD and cGVHD in the 6MM, GlobalData epidemiologists selected nationally-representative studies that provided the diagnosed incidence of aGVHD and cGVHD using the uniform validated diagnostic criteria and classification defined by the Center International Blood and Marrow Transplant Research standard grading system for aGVHD, and the standard criteria for cGVHD. In this analysis, GlobalData epidemiologists provided detailed, clinically relevant segmentations for the diagnosed aGVHD and cGVHD cases. Another strength of this analysis is that the same methodology was used across the 6MM, thereby allowing for meaningful global comparisons of the diagnosed incident GVHD cases.
Reasons to buy:
- Develop business strategies by understanding the trends shaping and driving the global GVHD market.
- Quantify patient populations in the global GVHD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the groups that present the best opportunities for GVHD therapeutics in each of the markets covered.
- Identify the number of incident and prevalent aGVHD and cGVHD cases.
Key Topics Covered:
1 Table of Contents
For more information visit http://www.researchandmarkets.com/research/dsdfsr/epicast_report